Affordable Access

Access to the full text

Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial

Authors
  • Schramm, Zachery A.1
  • Leroux, Brian G.2
  • Radick, Andrea C.1, 2
  • Ventura, Alicia S.3
  • Klein, Jared W.1
  • Samet, Jeffrey H.4, 3
  • Saxon, Andrew J.5
  • Kim, Theresa W.3
  • Tsui, Judith I.1
  • 1 University of Washington, 325 Ninth Avenue, Seattle, WA, 98104, USA , Seattle (United States)
  • 2 University of Washington, Seattle, WA, USA , Seattle (United States)
  • 3 Boston University School of Medicine and Boston Medical Center, Boston, MA, USA , Boston (United States)
  • 4 Boston University School of Public Health, Boston, MA, USA , Boston (United States)
  • 5 Center of Excellence in Substance Abuse Treatment and Education, VA Puget Sound Health Care System, Seattle, WA, USA , Seattle (United States)
Type
Published Article
Journal
Addiction Science & Clinical Practice
Publisher
BioMed Central
Publication Date
Jul 31, 2020
Volume
15
Issue
1
Identifiers
DOI: 10.1186/s13722-020-00203-9
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundOffice-based buprenorphine treatment of opioid use disorder (OUD) does not typically include in-person directly observed therapy (DOT), potentially leading to non-adherence. Video DOT technologies may safeguard against this issue and thus enhance likelihood of treatment success. We describe the rationale and protocol for the Trial of Adherence Application for Buprenorphine treatment (TAAB) study, a pilot randomized controlled trial (RCT) to evaluate the effects of video DOT delivered via a smartphone app on office-based buprenorphine treatment outcomes, namely illicit opioid use and retention.MethodsParticipants will be recruited from office-based opioid addiction treatment programs in outpatient clinics at two urban medical centers and randomized to either video DOT (intervention) delivered via a HIPAA-compliant, asynchronous, mobile health (mHealth) technology platform, or treatment-as-usual (control). Eligibility criteria are: 18 years or older, prescribed sublingual buprenorphine for a cumulative total of 28 days or less from the office-based opioid treatment program, and able to read and understand English. Patients will be considered ineligible if they are unable or unwilling to use the intervention, provide consent, or complete weekly study visits. All participants will complete 13 in-person weekly visits and be followed via electronic health record data capture at 12- and 24-weeks post-randomization. Data gathered include the following: demographics; current and previous treatment for OUD; self-reported diversion of prescribed buprenorphine; status of their mental and physical health; and self-reported lifetime and past 30-day illicit substance use. Participants provide urine samples at each weekly visit to test for illicit drugs and buprenorphine. The primary outcome is percentage of weekly urines that are negative for opioids over the 12-weeks. The secondary outcome is engagement in treatment at week 12.DiscussionVideo DOT delivered through mHealth technology platform offers possibility of improving patients’ buprenorphine adherence by providing additional structure and accountability. The TAAB study will provide important preliminary estimates of the impact of this mHealth technology for patients initiating buprenorphine, as well as the feasibility of study procedures, thus paving the way for further research to assess feasibility and generate preliminary data for design of a future Phase III trial.Trial Registration ClinicalTrails.gov, NCT03779997, Registered on December 19, 2018.

Report this publication

Statistics

Seen <100 times